Antibody titre as a surrogate of protection of the first malaria subunit vaccine, RTS,S/AS01
Open Access
- 1 December 2015
- journal article
- editorial
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (12) , 1371-1372
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialThe Lancet Infectious Diseases, 2015
- Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trialThe Lancet, 2015
- Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African SitesPLOS Medicine, 2014
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African ChildrenNew England Journal of Medicine, 2011
- A Field Trial to Assess a Blood-Stage Malaria VaccineNew England Journal of Medicine, 2011
- Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trialThe Lancet Infectious Diseases, 2011
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of ProtectionThe Journal of Infectious Diseases, 2009
- Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule.Proceedings of the National Academy of Sciences, 1988